

## B-Temia gains commercial access to Taiwan for human mobility device

23 September 2020 | News

B-Temia Asia obtains Taiwan Food & Drug Administration (TFDA) product license

B-Temia Asia, a joint venture company between Wistron Medical Technology Company and Canadian robotics tech company B-Temia Inc., incorporated in November 2019, announces that it has obtained the Taiwanese Food and Drug Administration (TFDA) product license for its powered human mobility device Keeogo<sup>TM</sup>.

This license opens a new market and allows the company to commercialize Keeogo<sup>TM</sup> in Taiwan, which represents one of the most important markets of the Asian territory. Last week, B-Temia Inc. obtained its 510(k) Clearance from the American Food and Drug Administration (FDA) as well as the CE Mark in December last year.

Keeogo<sup>TM</sup>, short for "Keep on going", is a powered mobility device for lower limbs developed by B-Temia. Based on the B-Temia's proprietary Dermoskeleton<sup>TM</sup> technology, Keeogo<sup>TM</sup> is a lightweight exoskeleton that detects, responds and supports an individual's movements with advanced software and motorized assistance, providing a true human-machine interface based on the individual needs.

Keeogo<sup>TM</sup> provides complementary knee strength and movement cues to assist trained healthcare professionals in rehabilitation and training of walking gait, sit-to-stand and stand- to-sit, squatting and stair climbing (ascent and descent).